Research programme: alpha-1 antitrypsin deficiency therapy - Gain Therapeutics
Latest Information Update: 18 Apr 2024
Price :
$50 *
At a glance
- Originator Gain Therapeutics
- Class Small molecules
- Mechanism of Action Alpha 1-antitrypsin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alpha 1-antitrypsin deficiency
Most Recent Events
- 18 Apr 2024 Preclinical trials in Alpha 1-antitrypsin deficiency in Switzerland (PO) (Gain Therapeutics Pipeline, April 2024)
- 04 Apr 2023 Early research in Alpha 1-antitrypsin deficiency in Switzerland (PO) (Gain Therapeutics pipeline, March 2023)